Process for producing transglutaminase
    22.
    发明授权
    Process for producing transglutaminase 有权
    转谷氨酰胺酶的制备方法

    公开(公告)号:US06833258B2

    公开(公告)日:2004-12-21

    申请号:US09892864

    申请日:2001-06-28

    CPC classification number: C12N9/1044 C12Y203/02013

    Abstract: The present invention relates to a high-yield process for producing high-activity, high-purity transglutaminase by refolding denatured microorganism-derived transglutaminase by reacting denatured transglutaminase in an aqueous medium under acidic conditions and reconstituting a higher-order enzymatically active state in an aqueous medium at a neutral pH.

    Abstract translation: 本发明涉及一种生产高活性,高纯度转谷氨酰胺酶的高产率方法,其通过在酸性条件下将变性转谷氨酰胺酶在水性介质中反应并重新折叠变性微生物转谷氨酰胺酶,并在水性中重新构建高级酶活性状态 培养基处于中性pH值。

    Method of purification of human BCDF
    23.
    发明授权
    Method of purification of human BCDF 失效
    人BCDF纯化方法

    公开(公告)号:US5610284A

    公开(公告)日:1997-03-11

    申请号:US275663

    申请日:1994-07-15

    CPC classification number: C07K14/5412 A61K38/00

    Abstract: There are disclosed (i) a purification process for obtaining a human BCDF having the intramolecular disulfide linkage and the stereostructure of natural type human BCDF which comprises subjecting to an oxidation reaction and a refolding treatment a reduced type human BCDF obtained by culturing a microorganism having a human BCDF gene integrated therein and solubilized with guanidine hydrochloride, characterized in that after the oxidation reaction, a gel filtration chromatographic treatment is conducted under the conditions of the guanidine hydrochloride concentration adjusted to 4-7M; (ii) a purification process for obtaining a natural type human BCDF monomer by removing the organic solvent from an organic solvent-containing solution of human BCDF, characterized in that the solution is passed through a gel filtration chromatographic column equilibrated with an organic solvent, followed by eluting according to a stepwise or linear gradient program; and (iii) a human BCDF purification process comprising an ion exchange chromatographic treatment and a reversed phase HPLC step, in combination (i) or (ii). According to these purification processes, it becomes possible to remove the impurities derived from a microorganism and human BCDF analogs, and the thus obtained natural type human BCDF has a high purity and can be utilized for pharmaceutical preparations.

    Abstract translation: 公开了(i)用于获得具有分子内二硫键的人BCDF和天然型人BCDF的立体结构的纯化方法,其包括进行氧化反应和重折叠处理,所述还原型人BCDF通过培养具有 人BCDF基因整合在其中并用盐酸胍溶解,其特征在于,在氧化反应后,在盐酸胍浓度调节至4-7M的条件下进行凝胶过滤色谱处理; (ii)通过从含有机溶剂的人BCDF中除去有机溶剂来获得天然型人BCDF单体的纯化方法,其特征在于使溶液通过用有机溶剂平衡的凝胶过滤色谱柱,随后 通过逐步或线性梯度程序洗脱; 和(iii)包含离子交换色谱处理和反相HPLC步骤(组合(i)或(ii))的人BCDF纯化方法。 根据这些纯化方法,可以除去由微生物和人BCDF类似物衍生的杂质,由此得到的天然型人BCDF具有高纯度,可用于药物制剂。

Patent Agency Ranking